critical event in the development of cell-mediated cytotoxicity is the receptor-stimulated release of granulederived proteins (1) . Before cytotoxic lymphocyte activation, preformed granules containing an array of cytotoxic and proteolytic molecules reside beneath the cell surface. Upon receptor recognition of susceptible targets, intracellular signals direct the transport of the granules toward the effector celltarget cell interface where they fuse with the plasma membrane and release their mediators. Previous work has focused on the role of phospholipase C (PLC)l-derived signals in regulating NK cell and CTL secretory responses (for reviews, see references [2] [3] [4] [5] .
Specifically, protein tyrosine kinase (PTK)-dependent activation of PLC is initiated after stimulation of NK cells through their FcR (6) (7) (8) (9) or of T lymphocytes through their 1 Abbreviations used in this paper: ADCC, antibody-dependent cellular cytotoxicity; PI 3-kinase, phosphatidylinositol 3-kinase; PIP, phosphatidylinositol-4-phosphate; PKC, protein kinase C; PI.C, phospholipase C; and FFK, protein tyrosine kinase.
TCR complex (10) (11) (12) (13) (14) . The subsequent PLC-catalyzed hydrolysis of phosphoinositides generates sn-l,2-diacylglycerol and inositol-l,4,5-trisphosphate, which in turn mediate the activation of PKC and the mobilization of intracellular calcium, respectively. Because PKC-activating phorbol esters, acting in conjunction with calcium ionophores, can induce granule release from NK cells and CTL (15) (16) (17) , it has been presumed that secretion initiated by cross-linking of multichain immune recognition receptors on these cell types is mediated via PKC-dependent pathways. Furthermore, it has been presumed that the proximal signals controlling FcR-or TCRinitiated secretion would be similar to those inducing granule release after NK cell recognition of susceptible tumor targets. Direct evidence for either of these assumptions is lacking.
Recently, it has been shown that Fc3~RIII -or TCR-initiated activation of FFK also results in the induction of a phosphatidylinositol 3-kinase (PI 3-kinase)-dependent pathway (18) (19) (20) . PI 3-kinase is a heterodimer composed of a catalytic p110 subunit and a regulatory p85 subunit (21) (22) (23) (24) (25) (26) . Upon activation, PI 3-kinase phosphorylates phosphoinositides at the D-3 position of the inositol ring to generate such prod-ucts as phosphatidylinositol 3-phosphate, phosphatidylinositol 3,4-bisphosphate, and phosphatidylinositol 3,4,5-trisphosphate (27) . These phosphoinositides are distinct from those used in the classical PLC-dependent signaling pathway, and it is therefore presumed that the lipids themselves are important molecules in signal transduction pathways. Specific attention has recently focused on the effects of PI 3-kinase on the sorting of vacuoles in yeast (28) , phtelet-derived growth factor (PDGF) receptor endocytosis (29) , histamine release from mast cells (30) , and cytoskdeton changes in thrombin-stimuhted platehts (31) . Taken together, these experimental observations suggest a potential general role for PI 3-kinase in the regulation of vesicular transport.
To investigate whether PKC-and/or PI 3-kinase-dependent pathways regulate granule release from cytotoxic lymphocytes, one would like to selectively interrupt each pathway and determine the subsequent effects on receptor-initiated secretion. With the recent identification of the bisindolylmaldmide GF109203X (32) and the microbial metabolite wortmannin (30) as sdective PKC and PI 3-kinase inhibitors, respectively, this experimental strategy is now possible. Using cloned human NK cells, we report here that FeyRIII-initiated granule release and antibody-dependent cdlular cytotoxicity (ADCC) are, in fact, reguhted by PKC-independent pathways. Rather, the profound inhibition of these functions by wortmannin suggests that FcR-initiated activation of PI 3-kinase modulates granule release from these cells. In contrast, the inability of wortmannin to inhibit direct antitumor NK cellmediated cytotoxicity suggests that alternative signaling pathways are used during this mode of killing.
Materiah and Methods
Chemical Reagents and Antibodies. Ionomycin and GF109203X
were obtained from Calbiochem-Novabiochem Corp. (La Jolla, CA). Streptolysin-O was purchased from Wellcome Diagnostics (Dartford, Enghnd). All other chemicals, unless otherwise noted, were obtained from Sigma Chemical Co. (St. Louis, MO). The antiFclk',/III mAb 3G8 (anti-CD16) (33) were purified by affinity chromatography over protein A agarose. F(ab')z fragments of goat anti-mouse IgG were purchased from Organon Teknika (West Chester, PA). The antiphosphotyrosine antibody-secreting hybridoma, 1G2, was a gift from A. Ik. Frackelton, Jr. (Brown University, Providence, ILl). 1G2 mAb purification has been previously described (34) . The rabbit anti-p85 antisera was raised against a GST-p85 fusion protein containing p85 amino acid residues 158-724.
Cell Lines. K562 (human erythroleukemia cell line) and P815
(murine mastocytoma call line) were obtained from American Type Culture Collection (Rockville, MD). The anti-CD16 3G8 hybridoma was generously provided by D. M. Segal (National Cancer Institute/National Institutes of Health, Bethesda, MD). These cell lines were maintained in RPMI 1640 supplemented with 10% bovine calf serum. Human PBL were isolated from the defibrinated blood of healthy donors by Ficoll-Hypaque density gradient centrifugation. Human CD16 + NK cell lines were isolated and characterized as previously described (6) .
CelIPermeabilization. NK cell permeabilization was performed as previously described (17 Cytotoxicity Assay. The SlCr-release assays measuring either direct NK cell-mediated cytotoxicity or ADCC were performed as previously described (6) . Spontaneous release was <15% of the maximum release for aU experiments. For results expressed as lyric units, 1 lytic unit is the number of cells required to give 20% specific 51Cr release.
PI 3-Kinase Assay. NK cell clones were cultured in RPMI 1640
medium supplemented with 10% bovine calf serum for 16 h before analysis. For each sample, 107 cells were treated as noted in figure legends, then diluted in ice cold lysis buffer (20 mM Tris, pH 7.4, 137 mM NaC1, 40 mM ~-glycerophosphate, 1 mM CaCI2, 1 mM MgCl2, 10% glycerol, 1% Triton X-100, 1 mM Na3VO4, 10 /~g/ml leupeptin, 5 /~g/ml aprotinin, 5 /~g/ml pepstatin A, and I mM PMSF). The cleared lysates were immunoprecipitated with either anti-p85 antibody bound to protein A-Sepharose beads, or 1G2 antibody covalently bound to Sepharose beads. After 45 min at 4~ the immunoprecipitates were washed three times with wash buffer (20 mM Tris, pH 7.4, 137 mM NaC1, 40 mM B-glycerophosphate, I mM CaC12, I mM MgCI2, 10% glycerol, 1% Triton X-100, 1 mM Ya3VO4, and 200 #M adenosine) and twice with 10 mM Tris, pH 7.4, 100 mM NaC1, 1 mM Na3VO~, and 200/~M adenosine. PI-3 kinase assays were performed as previously described (35) . The phosphatidylinositol-4-phosphate (PIP) standard was chromatographed in parallel sample lanes and visualized by staining with iodine vapors. Radiolabeled phosphoinositides were detected by autoradiography. In addition, 32p was quantitated after scanning the TIs plates using the Radioanalytic Imaging System (model 4000, AMBIS, Inc., San Diego, CA). (17) . Because the fluorescence assay for hexosaminidase has proven to be the more sensitive method for measuring low levels of granule exocytosis from human NK cells (17), results from the hexosaminidase assays are reported in this study. Cloned CD16 +, CD3-NK cells were first exposed to varying concentrations of the selective PKC inhibitor GF109203X (32) , and then stimulated with either 3G8 mAb (anti-Fc3'RIII)-coated polystyrene beads or a combination of the PKC- activating phorbol ester, PMA, and the calcium ionophore, ionomycin. As shown in the top pand of Fig. 1 , pretreatmerit of NK cells with concentrations of GF109203X that fully inhibited PMA/ionomycin-induced secretion did not alter FcK-induced granule release. These results suggest that although FKC activation can result in granule exocytosis from NK cells, Fcg-stimulated granule release is regulated by PKCindependent signaling pathways. (27, (36) (37) (38) (39) , antiphosphotyrosine immunoprecipitates from FcR-stimuhted NK cells were assayed for PI 3-kinase activity. Consistent with the recent report by Kanakaraj et al. (18), we found that Fc'yRIII stimulation of NK cells increased phosphotyrosine-associated PI 3-kinase activity (Fig. 2) . Specifically, PI 3-kinase activity increased within 2 rain of FcR ligation, peaked at 10 rains (sixfold increase), and declined by 30 rain.
Results

PKC-independent
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To evaluate the functional consequences of this PI 3-kinase activation, we characterized the effects of a recently described PI 3-kinase inhibitor, wortmannin (30) , in this experimental system. Wortmannin, a fungal metabolite, has been shown to specifically and irreversibly inhibit PI 3-kinase activity at nanomolar concentrations by binding to the p110 catalytic subunit of PI 3-kinase (30) . To evaluate its effects on cloned human NK cells, lysates from drug-treated cells were immunoprecipitated with anti-p85 antibodies and the immunoprecipitates were assayed for PI 3-kinase catalytic activity (Fig.  3) . Consistent with concentration-inhibition relationships observed'in other cell types (30) , wortmannin inhibited PI 3-kinase with an ICs0 of "~3 nM. Concentrations of wortmannin that fully inhibited PI 3-kinase activity in these NK cells had no effect on conjugate formation with susceptible targets (as quantitated by flow cytometry) or on FcR-initiated tyrosine kinase activation (as detected by antiphosphotyrosine immunoblotting) (data not shown). In parallel studies, pretreatment of NK cells with wortmannin potently inhibited FcK-induced secretion in a concentration-dependent manner with an ICs0 of •2 nM (Fig. 1, bottom) . It is important to note that although wortm~nnin blocked FcR-induced granule release from NK cells, PKC-dependent release from either intact cells stimulated with PMA/ionomycin or permeabilized cells stimulated with PMA in buffer containing high free Ca 2+ concentration was not inhibited by wortmannin (Fig. 1, bottom) . These data, together with the differential effects of GF109203X on NK cell secretion (Fig. 1, top) suggest that FcR-induced secretion is regulated by a PI 3-kinasedependent, PKC-independent pathway. Conversdy, pharmacologic activation by phorbol esters induces secretion via a separate PKC-dependent, PI 3-kinase-independent pathway. dent, cell-mediated killing. Pretreatment of cloned NK cells with wortmannin inhibited killing of both the anti-Fcq, KIII mAb-secreting hybridoma, 3G8 (Fig. 4, top) , and the P815 mastocytoma cell line that is normally rendered sensitive to NK cell-mediated cytotoxicity by coating with 3G8 mAb ("reverse ADCC") (Fig. 4, bottom) . Similar to the ICs0 for wortmanrtin's inhibition of FcR-induced granule release, wortmannin inhibited FcR-dependent killing of each target cell Figure 5 . The PKC inhibitor, GF109203X, fails to inhibit FcR-dependent NK cell-mediated cytotoxicity. Cloned NK cells were pretrcated for 15 min at 37~ with the indicated concentrations of GFlO9203X and the incubated for 1 h at 37~ with either SlCr-hbded 3G8 (anti-
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F~RIII) hybridoma cells (top) or slCr-labded I)815 cells bound to 3(;8 mAb (bottom).
type (i.e., 3G8 hybridomas or 3G8 mAb-coated P815 cells) with ICs0's of "~3 nM. Wortmannin also inhibited FcRdependent killing mediated by either clonal NK cell lines, polyclonal NK cell lines, or NK cells from PBL (data not shown). In repeated experiments, the percent inhibition by wortmannin was consistendy less for freshly isolated NK ceils than for IL-2-dependent NK cell lines. In contrast to the ability of the PI 3-kinase inhibitor, wortmannin, to reduce FcR-dependent NK cell-mediated killing, the PKC inhibitor, GF109203X, did not affect this mode of cellular cytotoxicity, as measured against either StCr-labded 3G8 hybridoma cells (Fig. 5, top) or 3G8 mAb-coated P815 cells (Fig.   5, bottom) . Taken together, these data suggest that FcK stimulation of NK cell granule release and cell-mediated cytotoxicity is selectively blocked by the PI 3-kinase inhibitor, wortmannin.
Separate Signaling Pathways Used during Alternative Modes of Ng Cell-mediated Cytotoxicity. NK cells can lyse target
cells either by FcR-dependent cytotoxidty of IgG-coated target ceils (iz, ADCC) or by direct antimmor cell-mediated killing. In both cases, granule release from the NK cells appears to be required for effective killing. However, it remains unclear whether the proximal signals functionally linked to granule release are the same or distinct. Having demonstrated that FcR-dependent cytotoxicity was blocked by the PI 3-kinase inhibitor, wortmannin, but not by the PKC inhibitor, GFlO9203X, we emended our analysis with these pharmacologic inhibitors to direct NK cell-mediated killing of the prototypical NK-sensitive tumor target, K562. Whereas FcRd~pendent killing of the hybridoma, 3G8, was wortmannin sensitive (Fig. 6 A, top) , and GF109203X resistant (Fig. 6  B, top) , killing of K562 was wortma_nnln resistant (Fig. 6 A, bottom) and GF109203X sensitive (Fig. 6 B, bottom) . These data suggest that although PI 3-kinase activation appears to Figure 6 . FoR-dependent cytotoxicity and direct antitumor cytot~icity are reguhted by separate signaling pathways. Cloned NK cells were preincubated for 15 rain at 37~ with the indicated concentrations of either wortmannin (,4) or GFlO9203X (B). Drug-treated ceUs were then incubated for 1 h with either StCrlabeled 3G8 (anti-Fc'yRIII) hybridoma cells (top) or slCr-labeled K562 tumor cells (bottom).
be critical for FcR-induced granule release and ADCC, a separate PKC-dependent pathway appears to regulate direct NK cell-mediated antitumor killing.
Discussion
Cytotoxic lymphocyte recognition of susceptible target cells elicits a diverse array of second messengers and the subsequent development of pleiotropic responses, including effects on granule release, cellular cytotoxicity, cytokine gene transcription, and cell surface receptor expression (2-5, 40, 41) . The heterogeneity of these biological responses has complicated attempts to link distinct proximal signaling events with specific downstream functional responses. In this study, we selectively inhibited separate signaling pathways generated after FcR ligation in NK ceUs and characterized the resulting effect on granule release and FcR-dependent cytotoxidty. Our results suggest that FcR stimulation of PI 3-kinase in NK cells is associated with both granule exocytosis and the generation of cellular cytotoxicity.
Early studies focused on the PTK-catalyzed activation of PLC as a central event during lymphocyte activation (for reviews, see references 2-5). With the subsequent demonstration that PKC-activating phorbol esters together with calcium ionophores could induce granule release from NK and T cells (15) (16) (17) , the consensus view was that FcR-and TCRinitiated secretory responses are controlled by PKC-dependent pathways. This notion was further bolstered by demonstrations that PKC could regulate granule exocytosis in other secretory cell types (e.g., mast calls, chromaffin cells, etc.) and could phosphorylate granule-associated proteins (42) (43) (44) (45) . To determine whether FcR-or TCK-initiated granule release is, in fact, mediated via a PKC-dependent pathway, one would like to assess the effects of selective and potent PKC inhibitors on this process. However, to date, most of the reported PKC inhibitors display poor selectivity both in vitro and in vivo. For example, H7 inhibits with similar potency PKC, cAMP-and cGMP-dependent protein kinase (ICs0 values of 3-6/~M) (46) . In addition, staurosporine, a potent PKC inhibitor (ICs0 = 10 riM) also effectively inhibits various PTK activities (47) . In contrast, a recent report (32) characterizes the highly selective and potent (ICs0 = 10 riM) effects of the bisindolylmaleimide GF109203X on PKC. Using this inhibitor, we report here that concentrations of GF109203X that fully block PMA-ionomydn-induced secretion from NK cells had no effect on FcK-initiated granule release. This result suggests that although there is a PKC-dependent pathway in NK cells that can modulate granule exocytosis, Fclk-initiated secretion is regulated by a PKC-independent pathway.
Recent attention has focused on PI 3-kinase as a separate second messenger system involved in cellular activation (27) . This enzyme is activated by a diverse array of receptors with intrinsic or associated FFK activities, including the PDGF, epidermal growth factor, CSF-1, insulin, and IL-2 receptors (for a review, see reference 27). Most recently, TCR and FcR ligation have also been shown to induce PI 3-kinase activation (18) (19) (20) . Yet, the downstream functional consequences of PI 3-kinase activation remain unclear, again due to di~cul-ties in sdectively inhibiting this pathway. However, a recent report (30) highlights the potent inhibitory activity of the fungal metabolite, wortmannin, on PI 3-kinase. Whereas wortmannin was originally characterized as an inhibitor of myosin light chain kinase when used at micromolar concentrations (48) , additional studies (30) indicated that at nearly 100-fold lower concentrations, wortmannin selectively and irreversibly inhibits PI 3-kinase. Wortmannin binds to the 100-kD catalytic subunit of PI 3-kinase resulting in inhibition with an ICs0 of 2 nM (30). We report here that wortmannin similarly inhibits PI 3-kinase activity in NK cells with an ICs0 of 3 nM and, also inhibits FcK-initiated secretion and cellular cytotoxicity with similar potency. These data suggest that PI 3-kinase activation in NK cells is associated with FcK-initiated granule release and ADCC.
Increasing information implicating potential role for PI 3-kinase in vesicular transport: (a) VPS34, a homolog of the catalytic subunit of PI 3-kinase, has been identified in the yeast Saccharomyces cerevisiae (28) . Yeast strains with VPS34 deletions or containing VPS34 point mutations exhibit severe defects in the sorting of vacuolar proteins (b) during thrombin-stimulated secretion from platelets, PI 3-kinase associates with the membrane cytoskeleton (31); (c) mutation of the PI 3-kinase binding site on the PDGF receptor alters endocytic trafficking of this receptor after growth factor binding (29) ; (d) pretreatment of the rat basophilic leukemia cell line, RBL-2H3, with wortmannin inhibits FceRI-initiated histamine release (30) . Our results extend these analyses by demonstrating that ADCC, which requires the formation of a microtubule-organizing center (49) and subsequent granule release at the effector-target interface, appears to require PI 3-kinase activation.
P1 3-kinase activity can be altered by multiple factors. PI 3-kinase associates with receptor proteins and other signaling molecules that contain a tyrosine phosphorylated consensus sequence, thus allosterically modulating its potential activity (36) (37) (38) (39) (50) (51) (52) . Tyrosine and/or serine-threonine phosphorylations may also modulate its enzymatic activity (52) (53) (54) . In addition, recent reports indicate that p85, the regulatory subunit of PI 3-kinase, associates with the SH3 domain of src family PTK (55, 56) and this interaction can increase PI 3-kinase catalytic activity (57) . Because FcR ligation results in the rapid activation of p56 ~k (9, (58) (59) (60) , and FFK activation appears to be requisite for granule release and ADCC (61, 62) , future work will need to focus on the role of p56 ~k itself or the proximal substrates of this FFK in coupling FcK stimulation to PI 3-kinase activation.
Finally, data presented here indicate that signaling events regulating granule release after recognition of Ab-coated targets (i.e., ADCC) vs susceptible tumor targets (i.e., direct NK cell-mediated cytotoxicity) are distinct. Early studies on NK cell activation focused on similarities in signaling initiated during these alternative modes of killing, i.e., early PTK activation, inositol phosphate release, and increase in intracellular free Ca 2+ (4, (6) (7) (8) (9) (61) (62) (63) (64) . However, we previously reported that pretreatment of NK cells with PKC-activating phorbol esters had differential regulatory effects on these alternative forms of NK cell activation (65) . In this report, we extend this analysis by comparatively evaluating the effects of wortmannin and GF109203X on secretion and killing induced by these separate modes of NK cell activation. These data suggest that although FcR-initiated effects on these processes proceed through PI 3-kinase--dependent pathways, direct recognition of susceptible tumor targets initiates granule release and killing through PKC-dependent pathways. These results point out that: (a) ADCC and direct natural cytotoxicity are triggered by fundamentally different biochemical events; and (b) it may be feasible to differentially modulate the effector functions of NK cells in patients.
